Eligibility for Anti-Amyloid Treatment
Oct 12, 2023•23 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Gregg Day talks with Dr. Vijay Ramanan about the clinical trial eligibility criteria for lecanemab treatment for participants with early Alzheimer disease and the generalizability of anti-amyloid treatment.
Read the related article in Neurology.
Visit NPub.org/Podcast for associated article links.
For the best experience, listen in Metacast app for iOS or Android